BioMarin's Vimizim OK'd in Japan for Morquio A
This article was originally published in Scrip
Executive Summary
BioMarin Pharmaceuticals won approval from Japan's Ministry of Health, Labor and Welfare to market Vimizim (elosulfase alfa) as a treatment for patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome.